David Thomson - 10 May 2025 Form 4 Insider Report for MANNKIND CORP (MNKD)

Reporting relationship: EVP Genl Counsel & Secretary
Issuer ticker: MNKD
Reported as of: 10 May 2025
Net transaction value: -$747,214
SEC form: 4
Accepted by SEC: 15 May 2025, 21:37:14 UTC
Prior SEC filing: 29 Aug 2024
Next SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ David Thomson

Key filing fact

David Thomson filed Form 4 for MANNKIND CORP (MNKD) on 15 May 2025.

Key facts

This page summarizes David Thomson's Form 4 filing for MANNKIND CORP (MNKD).
6 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 May 2025, 21:37.

Change

Previous filing in this sequence was filed on 29 Aug 2024.
Current net transaction value: -$747,214.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001297976 Primary reporting owner

Thomson David

Relationship: EVP Genl Counsel & Secretary
Address: 1 CASPER STREET, DANBURY
Signature: /s/ David Thomson
Signature date: 15 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNKD transaction

Common Stock, $0.01 Par Value

Award

Transaction value: $0
Shares: +105,600
Change %: +13%
Price: $0.000000
Shares after: 935,443
Date: 10 May 2025
Ownership: Direct
Footnotes: F1

MNKD transaction

Common Stock, $0.01 Par Value

Tax liability

Transaction value: $540,237
Shares: -118,473
Change %: -13%
Price: $4.56
Shares after: 816,970
Date: 12 May 2025
Ownership: Direct
Footnotes: F2

MNKD transaction

Common Stock, $0.01 Par Value

Tax liability

Transaction value: $56,380
Shares: -12,364
Change %: -1.5%
Price: $4.56
Shares after: 804,606
Date: 12 May 2025
Ownership: Direct
Footnotes: F2

MNKD transaction

Common Stock, $0.01 Par Value

Sale

Transaction value: $150,598
Shares: -32,179
Change %: -4%
Price: $4.68
Shares after: 772,427
Date: 13 May 2025
Ownership: Direct
Footnotes: F3, F4

MNKD transaction

Common Stock, $0.01 Par Value

Award

Transaction value: $0
Shares: +119,000
Change %: +15%
Price: $0.000000
Shares after: 891,427
Date: 13 May 2025
Ownership: Direct
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNKD transaction Derivative

Performance Restricted Stock Unit

Award

Transaction value: $0
Shares: +145,000
Change %
Price: $0.000000
Shares after: 145,000
Date: 13 May 2025
Ownership: Direct
Underlying class: Common Stock, $0.01 Par Value
Underlying amount: 145,000
Exercise price
Footnotes: F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022.

Footnote F2

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

Footnote F3

Transaction occurred pursuant to Rule 10B5-1 Plan established August 19, 2024.

Footnote F4

The weighted average sales price of the reported transaction was $4.68 based on a range of prices between $4.65 and $4.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F5

Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

Footnote F6

Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

Footnote F7

The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.